Celcuity, Inc. (NASDAQ:CELC – Get Free Report) has been given an average rating of “Moderate Buy” by the sixteen analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $151.79.
CELC has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research report on Tuesday, September 1st. Stifel Nicolaus lowered their price objective on Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Citigroup reissued a “market outperform” rating on shares of Celcuity in a report on Monday, November 9th. Wall Street Zen raised Celcuity from a “strong sell” rating to a “sell” rating in a report on Saturday, November 14th. Finally, Citizens Jmp restated a “market outperform” rating and set a $177.00 target price on shares of Celcuity in a research report on Monday, August 17th.
Get Our Latest Stock Analysis on CELC
Institutional Investors Weigh In On Celcuity
Celcuity Price Performance
CELC opened at $53.36 on Friday. Celcuity has a one year low of $53.20 and a one year high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 14.62 and a quick ratio of 14.59. The company’s 50 day simple moving average is $69.19 and its 200-day simple moving average is $96.86. The stock has a market capitalization of $2.62 billion, a P/E ratio of -11.33 and a beta of 0.16.
Celcuity (NASDAQ:CELC – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($1.21) earnings per share for the quarter, topping the consensus estimate of ($1.51) by $0.30. Sell-side analysts anticipate that Celcuity will post -5.08 earnings per share for the current fiscal year.
Celcuity Company Profile
Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.
Further Reading
- Five stocks we like better than Celcuity
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
